目的观察放射线联合p53基因及内皮抑素治疗C57BL/6小鼠前列腺癌皮下移植瘤的效果,并初步探讨其作用机制。方法建立C57BL/6小鼠前列腺癌皮下移植瘤模型。随机分成5组:空白组(A)、放射组(B)、放射线联合p53基因组(c)、放射线联合内皮抑素组(D)及放射线联合p53基因和内皮抑素组(E)。第1天c、E组瘤内注射p53基因腺病毒(1×10^10vp),第1-14天D、E组每日1次腹腔注射内皮抑素(1.5mg/kg)。第4天B、c、D、E组小鼠肿瘤区单次照射(6MVX线DT15Gy)。每日测量肿瘤体积;检测各组肿瘤标本P53、Ki67及血管内皮生长因子(VEGF)的表达及微血管密度值(MVD)。结果4个治疗组的肿瘤生长速度均低于空白组(P=0.000),其中E组生长最慢(P〈0.05)。免疫组织化学结果:4个治疗组P53的表达均明显低于空白组(P=0.000);4个治疗组Ki67的表达均高于空白组,但变化趋势不同:B、c组Ki67的表达值接近,均随时间的推移而逐渐升高(P=0.000),D、E组的表达则呈现波动性;第5天时E组VEGF的表达最低(P〈0.05);肿瘤生长过程中各组MVD值均持续升高,c、D、E3组MVD值在各时间均高于空白组(P〈0.05)。结论放射线联合p53基因及内皮抑素的抑瘤效果优于单独放射治疗及放射线联合p53基因或内皮抑素。三者均有自己的作用机制,但相互之间可以互相影响。
Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rhendostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1×10^10vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo ( P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P 〈 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 〉 0.05)and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P 〈 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest ( P 〈 0.05). An increased expression of MVD compared ~th the control was shown, and MVD in groups C, D and E were always higher than that in the control ( P 〈 0.05 ). Conclusions The limitation of radiotherapy could be overcome by combination with both p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and end